Results of Operations and Financial Condition. On August 10, 2026, Bionano Genomics, Inc. (the “Company”) issued a press release reporting its financial results for the second quarter ended June 30, 2026. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated into this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Secti…

Chief Medical Officer — Alka Chaubey, Ph.D.: The Chief Medical Officer resigned from the company.

Results of Operations and Financial Condition. On May 13 2026, Bionano Genomics, Inc. (the “Company”) issued a press release reporting its financial results for the first quarter ended March 31, 2026. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated into this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 1…

President and Chief Executive Officer — R. Erik Holmlin, Ph.D.: Dr. Holmlin was terminated as the Company’s President and Chief Executive Officer.

Results of Operations and Financial Condition. On March 23 2026, Bionano Genomics, Inc. (the “Company”) issued a press release reporting its financial results for the fourth quarter ended December 31, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated into this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Sec…

of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to th…

Results of Operations and Financial Condition. On November 13, 2025 , Bionano Genomics, Inc. (the “Company”) issued a press release reporting its financial results for the third quarter ended September 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated into this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes o…

Other Events. Press Releases On September 16, 2025, the Company issued a press release announcing the pricing of the Offering, and on September 17, 2025, the Company issued a press release announcing the closing of the Offering. A copy of each such press release is attached as Exhibit 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are hereby incorporated by reference herein. Cautionary Note Regarding Forward-looking Statements This Current Report on Form 8-K contains “for…

Entry Into a Material Definitive Agreement. Securities Purchase Agreement On September 16, 2025, Bionano Genomics, Inc. (the “Company”) commenced a best efforts public offering (the “Offering”) of an aggregate of (i) 4,925,000 shares (the “Shares”) of its common stock, par value $0.0001 per share, (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 75,000 shares of common stock (the “Pre-Funded Warrant Shares”), (iii) Series E warrants (the “Series E Warrant…

Results of Operations and Financial Condition. On August 14, 2025 , Bionano Genomics, Inc. (the “Company”) issued a press release reporting its financial results for the second quarter ended June 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated into this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Sect…

Member of the Audit Committee — Kristiina Vuori, M.D., Ph.D.: Dr. Kristiina Vuori was appointed to serve as a member of the Audit Committee of the Board.

Results of Operations and Financial Condition. On May 14, 2025 , Bionano Genomics, Inc. (the “Company”) issued a press release reporting its financial results for the first quarter ended March 31, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated into this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section…

to Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K. Forward-Looking S…

Entry into a Material Definitive Agreement. On February 4, 2025, Bionano Genomics, Inc. (the “Company”) suspended, and ceased offering any shares of its common stock, par value $0.0001 per share, (the “Common Stock”) pursuant to the prospectus supplement dated May 10, 2023, relating to the Sales Agreement (the “Sales Agreement”) by and between the Company and Cowen and Company, LLC (“Cowen”), dated March 23, 2021, as amended March 9, 2023. The Company provided written notice to Cowen terminat…

Termination of a Material Definitive Agreement. On February 4, 2025, Bionano Genomics, Inc. (the “ Company ”), provided notice of its termination, effective February 14, 2025, of that certain Sales Agreement, dated as of March 23, 2021, as amended March 9, 2023 (the “ Sales Agreement ”), by and among the Company and Cowen and Company, LLC (“ Cowen ”). As previously reported, pursuant to the terms of the Sales Agreement, the Company could offer and sell shares of its common stock, par value $0…

Material Modification to Rights of Security Holders. (a) On January 24, 2025, Bionano Genomics, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “ Restated Certificate ”), with the office of the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of 1:60 (the “ Charter Amendment ”). The Charter Amendment was authorized by the stockholders of the Company at the Company’s Special…

of this Current Report on Form 8-K shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and it shall be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act. Forward-Looking Statements This Current Report on Form 8-K and accompany press release contain forward-looking statements within the meaning of the Private Securities Litigation R…

Entry into a Material Definitive Agreement. Registered Direct Offering On January 3, 2025, Bionano Genomics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market consistent with the rules of the Nasdaq Stock Market (the “Offering”) (i) an aggregate of 22,900,000 shares (the “Shares”) of the Company’s common s…

Other Events. In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Cooley LLP, regarding the validity of the issuance and sale of the Shares, the Warrants and the Warrant Shares, which opinion is attached as Exhibit 5.1 to this Current Report. Forward-Looking Statements This Current Report contains forward-looking statements, including, without limitation, statements relating to the Company’s expectations regarding the completion of…

relating to the Shares and the Unregistered Conversion Shares is set forth under

and the related exhibit are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such a filing. Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” wit…

Entry into a Material Definitive Agreement. Settlement Agreement and First Amendment to Securities Purchase Agreement and Debentures On December 31, 2024, Bionano Genomics, Inc. (the “Company”) entered into a settlement agreement and amendment (the “Amendment”) relating to its outstanding senior secured convertible debentures due May 24, 2026 (the “Debentures”) with certain accredited investors (the “Investors”) and JGB Collateral LLC, as collateral agent for the Investors (the “Collateral Ag…

Results of Operations and Financial Condition. On November 13, 2024 , Bionano Genomics, Inc. (the “Company”) issued a press release reporting its financial results for the third quarter ended September 30, 2024. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated into this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes o…

Entry into a Material Definitive Agreement. Registered Direct Offering On October 30, 2024, Bionano Genomics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market consistent with the rules of the Nasdaq Stock Market (the “Offering”) (i) an aggregate of 9,881,113 shares (the “Shares”) of the Company’s common s…

Other Events. In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Cooley LLP, regarding the validity of the issuance and sale of the Shares, the Purchase Warrants and the Warrant Shares, which opinion is attached as Exhibit 5.1 to this Current Report. Forward-Looking Statements This Current Report contains forward-looking statements, including, without limitation, statements relating to the Company’s expectations regarding the comp…